2a follow2up study.Dermatology,1996,193 (4):321Thalidomide in the treatment of aphthosis and Behcet's disease.4years'experience.Med Cutan Ibero Lat Am,1982,10 (2):103.
3Healy CM,Carvalho D,Pearson JD.Raised anti2endothelial cellautoantibodies (AECA),but not anti2neutrophil cytoplasmicautoantibodies (ANCA),in recurrent oral ulceration:modulation of AECA binding by turnour necrosis factor2alpha (TNF2alpha) andinterferon2gamma (IFN2gamma).Clin Exp Immunol,1996,106(3):523.
6Revuz J, Guillaume JC, Janier M, et a/.Crossover study of thalidomide vs. placebo in severe recurrent aphthous sto- matitis [J]. Arch Dermatol, 1990,126 ( 7 ) : 923.
7Ramirez-Amador VA, Esquivelopedraza L, Ponce-de-Leon S, et a/.Thalidomide as therapy for human immunodefi- ciency virus-related oral ulcers: a double-blind place- bo-controlled clinical trial[J].Clin Infect Dis, 1999, 28 (4):892.
8Jacobson JM, Greenspan JS, Spritzler J, et al.Thalidomide for the treatment of oral aphthous ulcer in patients with human immunodeficiency virus infection[J]. N Engl J Med, 1997,336(21) : 1 487.
9Jacobson JM, Spritzler J, Fox L, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection[J]. J Infect Dis, 1999,180(1) : 61.
10Jacobson JM, Greenspan JS, Spritzler J, et al.Thalidomide in low intermittent doses does not prevent recurrence ofhuman immunodeficiency virus-associated aphthous ul- cers[J]. J Infect Dis, 2001,183 (2) : 343.
